Search
Esperion Therapeutics Inc
ESPRAdd to Watchlist
3.180USD
0.0000.00%
Close 07-10 16:00（ET）
819.46MMarket Cap
LossP/E TTM
Esperion Therapeutics Inc (ESPR) Stock Price Target & Forecast
Target Price
3.160USD-0.63%
ESPR Analyst Recommendation Trends
In the current month, ESPR has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ESPR average Analyst price target in the last month is 3.160.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
1
1
1
1
1
1
0
0
5
5
5
5
5
5
0
0
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
0
0
8
8
8
8
8
8
ESPR Analyst Rating for Peer Comparison
Updated: Oct 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Regeneron Pharmaceuticals Inc
REGN
6
15
10
0
0
31
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, ESPR EPS is projected to reach -0.008 in FY2026Q2, following reported EPS of -0.100 in FY2026Q1. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q3
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
Forecast
-0.06
0.24
-0.03
-0.01
-0.00
Actual
-0.16
0.26
-0.10
--
--
Surprise
-182.31%
+8.30%
-199.22%
--
--
FAQs
What is Esperion Therapeutics Inc's expected revenue for the next quarter?
Esperion Therapeutics Inc's expected revenue is 90.95M.
What is Esperion Therapeutics Inc's price target?
Analysts forecast that Esperion Therapeutics Inc's price target is USD 4.50, with the highest forecast at USD 16.00 and the lowest forecast at USD 1.72.
How have Esperion Therapeutics IncESPR's recent earnings per share performed?
The market expectation was USD -0.10, while Esperion Therapeutics IncESPR's earnings per share (EPS) for the previous quarter was USD 0.26. EPS for the next quarter is expected at USD -0.01.
What is the analyst rating for Esperion Therapeutics Inc?
Based on the ratings of Esperion Therapeutics Inc's stock from 0 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.